[go: up one dir, main page]

MA30373B1 - Acides 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]0xy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoique ou propenoique en tant qu'antagonistes des recepteurs h1 et h3 pour le traitement de troubles inflammatoires et/ou allergiques - Google Patents

Acides 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]0xy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoique ou propenoique en tant qu'antagonistes des recepteurs h1 et h3 pour le traitement de troubles inflammatoires et/ou allergiques

Info

Publication number
MA30373B1
MA30373B1 MA31023A MA31023A MA30373B1 MA 30373 B1 MA30373 B1 MA 30373B1 MA 31023 A MA31023 A MA 31023A MA 31023 A MA31023 A MA 31023A MA 30373 B1 MA30373 B1 MA 30373B1
Authority
MA
Morocco
Prior art keywords
piperidinyl
treatment
naphthalenyl
propanoic
antagonists
Prior art date
Application number
MA31023A
Other languages
English (en)
Inventor
Panayiotis Alexandrou Procopiou
Simon Teanby Hodgson
Brugarolas Maria Victoria Vinader
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0525897A external-priority patent/GB0525897D0/en
Priority claimed from GB0623217A external-priority patent/GB0623217D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30373B1 publication Critical patent/MA30373B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule (I) ou un sel dudit composé où le cycle naphtalène peut être substitué en position 2, 3, 4, 5, 6, 7 ou 8 par R1, R1 représentant -CH2CH2COOH ou -CH=C(CH3)COOH, ainsi que des procédés de synthèse dudit composé ou de son sel, des préparations contenant ledit composé ou son sel et leur emploi dans le traitement de diverses maladies telles que la rhinite allergique..
MA31023A 2005-12-20 2008-06-11 Acides 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]0xy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoique ou propenoique en tant qu'antagonistes des recepteurs h1 et h3 pour le traitement de troubles inflammatoires et/ou allergiques MA30373B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0525897A GB0525897D0 (en) 2005-12-20 2005-12-20 Compounds
GB0623217A GB0623217D0 (en) 2006-11-21 2006-11-21 Compounds

Publications (1)

Publication Number Publication Date
MA30373B1 true MA30373B1 (fr) 2009-05-04

Family

ID=37845266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31023A MA30373B1 (fr) 2005-12-20 2008-06-11 Acides 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]0xy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoique ou propenoique en tant qu'antagonistes des recepteurs h1 et h3 pour le traitement de troubles inflammatoires et/ou allergiques

Country Status (24)

Country Link
US (1) US7989629B2 (fr)
EP (2) EP1963307B1 (fr)
JP (2) JP4445570B2 (fr)
KR (1) KR20080087102A (fr)
AR (1) AR058109A1 (fr)
AT (1) ATE449769T1 (fr)
AU (1) AU2006328512B2 (fr)
BR (1) BRPI0620218A2 (fr)
CA (1) CA2634391A1 (fr)
CR (1) CR10102A (fr)
CY (1) CY1110601T1 (fr)
DE (1) DE602006010737D1 (fr)
DK (1) DK1963307T3 (fr)
EA (1) EA014354B1 (fr)
ES (1) ES2337187T3 (fr)
IL (1) IL191967A0 (fr)
MA (1) MA30373B1 (fr)
NO (1) NO20082695L (fr)
PE (1) PE20071068A1 (fr)
PL (1) PL1963307T3 (fr)
PT (1) PT1963307E (fr)
SI (1) SI1963307T1 (fr)
TW (1) TW200730498A (fr)
WO (1) WO2007071691A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285803A4 (fr) 2008-05-23 2011-10-05 Amira Pharmaceuticals Inc Inhibiteur de la protéine d activation de 5-lipoxygénase
US20120149731A1 (en) 2009-06-29 2012-06-14 Glaxo Group Limited New medical use
JP4785963B2 (ja) 2009-10-09 2011-10-05 キヤノン株式会社 固体撮像装置
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
KR101640756B1 (ko) 2014-10-28 2016-07-19 이종찬 전동 드릴 장착용 내시경 캡
EP3758689A4 (fr) * 2018-03-01 2022-01-12 Ferox Therapeutics LLC Méthodes de prévention et de traitement de l'hypoglycémie chez des patients atteints de diabète de type 1 et de type 2
CA3173172A1 (fr) 2020-03-26 2021-09-30 Christopher D. Kane Inhibiteurs de cathepsine pour la prevention ou le traitement d'infections virales

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0633776B1 (fr) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Composes destines a traiter les maladies allergiques et inflammatoires
WO1993023431A1 (fr) 1992-05-14 1993-11-25 Baylor College Of Medicine Recepteurs d'hormones steroides mutees, procede d'utilisation et commutateur moleculaire pour therapie genique
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DK0765308T3 (da) 1994-06-15 2000-09-11 Wellcome Found Enzyminhibitorer
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
US6255303B1 (en) 1998-03-14 2001-07-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone PDE III/IV inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
EP1175422A2 (fr) 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Composes modulateurs de recepteur de progesterone tetracycliques et procedes
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
ATE416184T1 (de) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
PL393155A1 (pl) 2001-09-14 2011-03-28 Glaxo Group Limited Pochodne fenetanoloaminy do leczenia chorób układu oddechowego
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
DE60309829T2 (de) 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
US6831093B2 (en) 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
KR101022977B1 (ko) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1521733B1 (fr) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
PL375442A1 (en) 2002-07-18 2005-11-28 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
WO2004024728A2 (fr) 2002-09-16 2004-03-25 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2499150A1 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003274053A1 (en) * 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
EP1554264B1 (fr) 2002-10-22 2007-08-08 Glaxo Group Limited Derives d'arylethanolamine a usage medicinal
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
BR0315720A (pt) 2002-10-28 2005-09-06 Glaxo Group Ltd Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006000398A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Derives de 2,3-benzoxazine utilises en tant que modulateurs non steroidiens du recepteur glucocorticoide
WO2006000401A1 (fr) 2004-06-28 2006-01-05 Glaxo Group Limited Oxazines substituees utilisees comme modulateurs du recepteur glucocorticoide
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
TW200811116A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CR10102A (es) 2008-09-22
PT1963307E (pt) 2010-03-03
EP1963307A1 (fr) 2008-09-03
EA200801342A1 (ru) 2008-12-30
IL191967A0 (en) 2008-12-29
AU2006328512B2 (en) 2011-06-23
EP2157087A1 (fr) 2010-02-24
PL1963307T3 (pl) 2010-05-31
BRPI0620218A2 (pt) 2011-11-01
US7989629B2 (en) 2011-08-02
NO20082695L (no) 2008-09-16
CA2634391A1 (fr) 2007-06-28
TW200730498A (en) 2007-08-16
SI1963307T1 (sl) 2010-03-31
ATE449769T1 (de) 2009-12-15
HK1120265A1 (en) 2009-03-27
KR20080087102A (ko) 2008-09-30
PE20071068A1 (es) 2007-12-13
JP2009520001A (ja) 2009-05-21
JP4445570B2 (ja) 2010-04-07
AR058109A1 (es) 2008-01-23
JP2009235087A (ja) 2009-10-15
DK1963307T3 (da) 2010-04-06
AU2006328512A1 (en) 2007-06-28
WO2007071691A1 (fr) 2007-06-28
ES2337187T3 (es) 2010-04-21
DE602006010737D1 (de) 2010-01-07
US20080312280A1 (en) 2008-12-18
EP1963307B1 (fr) 2009-11-25
CY1110601T1 (el) 2015-04-29
EA014354B1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
MA30373B1 (fr) Acides 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]0xy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoique ou propenoique en tant qu'antagonistes des recepteurs h1 et h3 pour le traitement de troubles inflammatoires et/ou allergiques
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EA200500006A1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
MA32798B1 (fr) Acides naphtylacétiques
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
RU2009126745A (ru) Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств
MA30394B1 (fr) Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p
MA38170B1 (fr) Nouveaux acides indanyloxydihydrobenzofuranylacétiques
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
ATE540932T1 (de) Hydantoin-derivate als antibakterielle wirkstoffe
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MA38217B1 (fr) Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2
MA33295B1 (fr) Nouvelle formulation de diclofénac
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus